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Abstract 
 
Cell migration and endothelial cell tubulogenesis are both processes which are altered in 
many cancers. Black raspberries and their components have been shown to inhibit tumor 
growth and neovascularization in vivo, but the active components in black raspberries are 
still being identified. This experiment used two assays to determine the effect of black 
raspberry components on tumor cell migration, endothelial cell migration, and endothelial 
cell tubulogenesis. Ellagic acid and quercetin effectively inhibited migration of both cell 
types. Human Umbilical Vascular Endothelial Cell (HUVEC) migration was inhibited by 
ellagic acid at 2 µM (30.9% control ± 10.1%, P ≤ 0.04), and by quercetin at 10 µM 
(24.1% control ± 2.5%, P ≤ 0.02). Migration of the esophageal tumor cell line (TE-8) was 
studied to evaluate differences between endothelial cell and tumor cell sensitivity to each 
compound. Migration of TE-8 cells was inhibited by ellagic acid at 2 µM (43.1% control 
± 15.9%, P ≤ 0.04), and by quercetin at 20 µM (40.3% control ± 18.7%, P ≤ 0.05). Both 
ellagic acid and quercetin inhibited endothelial cell tubulogenesis qualitatively at 2 µM. 
However, HUVEC morphology differed between the two treatments. Ellagic acid 
inhibited tubulogenesis and cell elongation at 2 µM, whereas quercetin inhibited 
tubulogenesis, but not cell elongation at 2 µM. 
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Introduction 
 
Many foods are known to possess anti-carcinogenic properties and can be used as 
nutraceutical foods for cancer prevention, or developed into chemotherapeutic agents. 
Like many berries, the black raspberry (Rubus occidentalis, BRB) contains both known 
and suspected anti-carcinogenic compounds, such as anthocyanins, ellagitannins, 
flavanoids, and flavonoids1,2,3. Current research indicates that the anti-carcinogenic 
activity observed in black raspberries may be a synergistic effect of more than one 
compound acting on multiple cellular pathways, because direct extracts have more 
activity than most fractions or isolated compounds alone4,5. However, specific 
compounds with anti-carcinogenic activity in black raspberries have been identified, such 
as cyanidin glycosides, ellagic acid, gallic acid, and quercetin6,7,8. At least three cyanidin 
glycosides, a type of anthocyanin, are known to inhibit nuclear factor kappa B (NFκB) 
and activator protein-1 (AP-1), which play a role in carcinogenesis9.  
This study examined the anti-migratory and anti-angiogenic effects of a cyanidin 
chloride derivative, keracyanin chloride. Studies have shown that ellagic acid, a phenolic 
compound, inhibits endothelial cell migration and tubulogenesis, but little is known about 
the synergistic effect it may have in BRBs10. The effects of ellagic acid were compared to 
two BRB fractions in order to determine if a synergistic effect was taking place. The 
flavonoid quercetin also has known anti-carcinogenic effects, such as tyrosine kinase 
inhibition, matrix metalloproteinase-2 inhibition, and free-radical scavenging11. The 
purpose of this study was to compare the anti-migratory and anti-angiogenic capability of 
pure ellagic acid, keracyanin, and quercetin to two BRB fractions in order to determine if 
a synergistic interaction was taking place, and to examine differences between each 
treatment that could indicate different cellular mechanisms were being affected. 
  
Although cancers vary greatly in genotype, there are commonalities in the cellular 
processes that become altered during transformation of a normal cell into a malignant 
cancer. Two of these processes are angiogenesis and cell migration; both processes are 
limited in normal cells, and are commonly acquired during carcinogenesis. Because 
oxygen and nutrient diffusion to cells within the body is limited by proximity to the 
supplying vascular tissue, tumors larger than 1-2 mm3 must acquire the ability to induce 
angiogenesis in order to continue growth12. Angiogenesis in human adults is normally 
limited, and occurs only during events such as menses and wound healing13. This makes 
prevention of tumor neovascularization a good potential target for chemopreventative 
agents. Anti-angiogenic treatment is also attractive because an endothelial cell’s genome 
is more stable than that of a tumor cell, so drug resistance is less likely to develop14. The 
most effective treatments will most likely combine anti-angiogenic treatment with more 
traditional chemotherapy aimed at prevention of tumor metastasis. Tumor metastasis 
depends on the ability of the cancer cells to migrate to other locations in the body, and is 
generally associated with poor prognosis15. This is a complicated process, and may be 
further complicated by individual differences between tumors. The process of metastasis 
starts when tumor cells detach from the primary tumor. This may be due to a number of 
cellular factors, or necrosis in the primary cell mass16. Tumor cell detachment is followed 
by migration into the surrounding tissue (intravasation), and migration into vascular 
tissue (extravasation). Most of the tumor cells will die, but those that survive may 
circulate to a new location in the body, extravasate again, and form a new tumor17. 
Chemotherapeutic agents that inhibit cell migration may be able to prevent metastasis, 
and limit the scope of the cancer. 
 
The purpose of this project was to test potential chemotherapeutic agents in the 
components of BRBs for the in vitro inhibition of cell migration in human esophageal 
tumor cells (TE-8 cells), and the inhibition of either cell migration or tubulogenesis 
(microvessel formation) in human umbilical vascular endothelial cells (HUVECs).          
 
Materials & Methods 
 
Compounds. Anthocyanin (keracyanin chloride), ellagic acid, and quercetin (dihydrate) 
were obtained as pure compounds (Sigma, St Louis, MO). Two black raspberry fractions 
were obtained  from a previous experiment (courtesy of Dr. Gary Stoner)18. The 80/20 
fraction was extracted from lyophilized BRBs using 80% ethanol and 20% water. The 
residue fraction consisted of the lyophilized BRB remainder after extractions with 
pentane, methylene chloride, ethanol, and water. Each compound was initially dissolved 
in filtered dimethylsulfoxide (DMSO), then diluted in Medium 131 (Cascade Biologics, 
Portaland, OR) to the appropriate concentration. The concentration of DMSO was kept 
below 0.1% (v/v).   
Cell Migration Assay. TE-8 cells (a kind gift from Xiao-Chun Xu)19 and HUVECs 
(Cascade Biologics, Portland, OR) were each seeded into 24 well culture plates and 
allowed to grow to confluence. Two perpendicular lines were scraped through each well 
with a 1mm wide cell scraper (Fisher Scientific, Pittsburgh, PA). The cells were rinsed 2x 
with Hepes Buffered Saline (Athena ES, Baltimore, MD) before adding anthocyanin, 
ellagic acid, 80/20 fraction, quercetin, or residue fraction at 0, 1, 2, 5, 10, 20, and 30 µM 
(µg/ml was used for the fractions). Each concentration was assayed in duplicate. The 
cells were incubated 48h at 37°C, fixed for 10 min in buffered formalin, and stained with 
0.3% crystal violet for 5 min. Computer image analysis (Simple PCI, Compix Inc., 
Sewickley, PA) was used to count the total number of cells in representative views of 
each well (4 images per concentration, taken at 40x), and to enumerate the number of 
cells in a 1x1mm area which had been scraped (fig. 1). The standard error of the mean 
was determined for each point, and the P value determined using a two-tailed t-test 
assuming equal variances. 
Cytotoxicity Assay. Ellagic acid and quercetin were tested for cytotoxicity in both cell 
types using the CCK colorimetric assay (Dojindo Molecular Technologies, Gaithersburg, 
MD) in a 96 well plate. Cells were seeded at 5,000 cells/well, allowed to grow to 
confluence, and treated identically to the cell migration assay until completion of the 
incubation period. CCK-8 solution (10 µl/well) was added, and the plates were incubated 
at 37°C for 1 hour. The absorbance was measured at 450 nm. Absorbance was plotted 
relative to the control, standard error of the mean was determined for each point, and the 
P values were determined using a t-test, as above. 
Tubulogenesis Assay. Matrigel (BD Biosciences, San Jose, CA) was diluted 1:1 with 
Medium 131on ice. Each compound to be tested was included at the appropriate 
concentration in the Matrigel layer. The diluted Matrigel was put into a 96 well culture 
plate (60 µl per well), and incubated 15 min at 37°C to allow gelling. Dissociated 
HUVECs were diluted in Medium 131 such that the cell concentration was 1 x 104 at 
each compound concentration. The compound/HUVEC mixture was   added onto the 
Matrigel layer in each well(100 µl, or 1000 cells per well). Ellagic acid and quercetin 
were added at 0, 2, 5, 20, 50, and 100 µM in triplicate, and incubated at 37°C for 24h. 
The cells were fixed in buffered formalin for 10 min. Images were taken of the unstained 
cells(fig 2), and observed for cell elongation or tube formation qualitatively (quantitative 
data was not practical using current software).   
 
Results 
 
Cell Migration. Migration of both HUVECs and TE-8 cells was inhibited by treatment 
with ellagic acid and quercetin. Both cell types were affected by ellagic more than by 
treatment with quercetin. Anthocyanin, 80/20 fraction, and residue fraction showed no 
statistically significant inhibition of either cell type at the concentrations used. HUVEC 
migration (fig. 3) was inhibited by ellagic acid at 2 µM (30.9% control ± 10.1%, P ≤ 
0.04), and by quercetin at 10 µM (24.1% control ± 2.5%, P ≤ 0.02). TE-8 cell migration 
(fig. 3) was inhibited by ellagic acid at 2 µM (43.1% control ± 15.9%, P ≤ 0.04), and by 
quercetin at 20 µM (40.3% control ± 18.7%, P ≤ 0.05). HUVECs were more sensitive to 
quercetin than TE-8 cells at the same concentration. 
Cytotoxicity. Quercetin was cytoxic in both cell types. Ellagic acid was cytoxic in 
HUVECs, but was not significantly cytoxic in TE-8 cells (fig. 4). Ellagic acid showed 
cytotoxicity in HUVECs at 1 µM (P ≤ 0.008), but was not cytoxic in TE-8 cells at the 
concentrations tested. Quercetin was cytoxic in HUVECs at 5 µM (P ≤ 0.002), and was 
cytoxic in TE-8 cells at 10 µM (P ≤ 0.02).   
Tubulogenesis. HUVEC tubulogenesis was qualitatively inhibited by both ellagic acid 
and quercetin at 2 µM. Cell elongation was observed in wells treated with quercetin in a 
dose-dependent manner, but no cell elongation was observed in wells treated with ellagic 
acid at the concentrations tested. Cell viability was tested qualitatively by placing a 
sample of the treated cells into a 96 well plate; cell growth was observed after incubation 
at 37°C for 48h. Cell viability was decreased by both ellagic acid and quercetin relative to 
the control.   
 
Discussion 
 
Cell Migration and Cytotoxicity. Cell migration was effectively inhibited by ellagic 
acid and quercetin, but was not significantly inhibited by anthocyanin, 80/20 fraction, or 
residue fraction. The inability of keracyanin to inhibit cell migration at the concentrations 
tested indicates that not all cyanidin glucosides possess equal anti-carcinogenic activity, 
or that cyanidin glucoside derivatives do not have the same level of activity as cyanidin 
glucosides themselves. Further research comparing keracyanin to cyanidin glucosides 
with known anti-carcinogenic activity will be necessary to determine the relationship. 
Neither of the BRB fractions (80/20 and residue), were effective migration inhibitors at 
the concentrations tested, so a synergistic effect was not observed. This could be because 
the active compounds in BRBs are not a large enough portion of the respective extracts to 
be effective at the tested concentrations, since ellagic acid and quercetin are both found in 
BRBs, and both effectively inhibited migration. Ellagic acid inhibited migration at lower 
concentrations than quercetin in both cell types, but there were significant differences in 
cytotoxicity between HUVECs and TE-8 cells. Ellagic acid was cytoxic for HUVECs at 
low concentrations, so would be the more effective of the two compounds at targeting 
HUVEC migration inhibition.  
The observed differences in cytotoxicity and effective dose in each cell type 
indicate that ellagic acid and quercetin may act via different cellular mechanisms. Ellagic 
acid’s lack of cytotoxicity in TE-8 cells suggests an altered molecular pathway may be 
present in this tumor cell line, which could allow this cell line to develop resistance 
against ellagic acid. This changed pathway may allow ellagic acid to inhibit cell 
migration at the same concentration in both cell types, while preventing cytotoxicity of 
the compound in TE-8 cells. Differences in dose-response were observed in the treatment 
of HUVEC and TE-8 cells with quercetin. Equivalent inhibition of migration and 
cytotoxicity were achieved in TE-8 cells at twice the concentration used in HUVECs. 
This indicates that quercetin may be acting on the same molecular pathways in both cell 
types, but individual differences between cell lines exist. Quercetin’s inhibition of 
migration and angiogenesis is consistent with previous research, which found quercetin 
acts upon COX-2 (cyclooxygenase-2) and NFκB20.  Further experiments will be needed 
to test the molecular pathway hypothesis for both quercetin and ellagic acid. Gene 
expression of possible targets will be studied using RNA extraction, and RT-PCR.    
Tubulogenesis. Since ellagic acid and quercetin inhibited HUVEC tubulogenesis at all 
concentrations tested, further study will be necessary to determine if a dose-response 
relationship exists. Inhibition of tubulogenesis was effective at equivalent or lower 
concentrations for both compounds examined, suggesting that targeting HUVEC 
angiogenesis may be more effective than targeting HUVEC migration. The cell 
elongation observed in the wells treated with quercetin, but not those treated with ellagic 
acid is consistent with the difference in effective dose between the two compounds in the 
migration assay. Further research will also be necessary to determine what step in the 
process of angiogenesis is inhibited. Analysis of gene expression during treatment with 
either ellagic acid or quercetin may indicate whether the anti-angiogenic effects of these 
compounds act via different mechanisms. Gene expression in the HUVEC tubulogenesis 
assay will also be compared to gene expression in the cell migration assay in order to 
determine if different pathways account for the differences in inhibitory concentration 
between the two assays. Further research may also include mixed cultures, in which 
HUVEC and TE-8 cells are combined in a spheroid to examine whether or not the tumor 
cells influence migration or tubulogenesis of HUVEC cells21. 
 These results have shown that there are multiple compounds in black raspberries 
that can affect endothelial cell angiogenesis and cell migration. This provides the basis 
for future cell culture research on the interactions between endothelial cells in spheroids, 
and molecular research on the mechanisms involved in the inhibition of tubulogenesis 
and cell migration.  
Figures 
 
 
 
Figure 1. Cell migration of HUVECs (top row) and TE-8 cells (bottom row). The first 
column shows migration in excess of 100% of the control (top: anthocyanin at 20 µM, 
bottom: residue fraction at 1 µM). The second column shows the amount of migration 
observed in the controls. The third and fourth columns show migration at the lowest 
inhibitory concentration for ellagic acid (2 µM for both cell types) and quercetin (10 µM 
for HUVECs, 20 µM for TE-8 cells) respectively. The black boxes indicate an area 
1x1mm in each image which was used to quantify cell migration relative to the control. 
 
 
 
Figure 2. Tubulogenesis of HUVEC on a layer of Matrigel after treatment with ellagic 
acid (top) and quercetin (bottom). The left column shows extensive tube formation in the 
control wells. The second column from the left shows the complete inhibition of HUVEC 
tubulogenesis by both compounds at 2 µM. The third column from the left shows 
enlargements of the images at 2µM, indicating the different morphology of the HUVEC 
cells; ellagic acid inhibits cell elongation at 2 µM, while quercetin does not. The 
rightmost column shows the complete inhibition of HUVEC tubulogenesis at 100 µM for 
both compounds (some compound precipitation is evident in both images).  
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Figure 3. Migration of HUVEC and TE-8 cells as percent of control. The number of cells 
which migrated into a 1x1 mm area which had been scraped clean of cells after 24 hours 
was counted, and compared to the number of cells which migrated in the controls for 
each concentration. Human Umbilical Vascular Endothelial Cell (HUVEC) migration 
was inhibited by ellagic acid at 2 µM (30.9% control ± 10.1%, P ≤ 0.04), and by 
quercetin at 10 µM (24.1% control ± 2.5%, P ≤ 0.02). Migration of TE-8 cells was 
inhibited by ellagic acid at 2 µM (43.1% control ± 15.9%, P ≤ 0.04), and by quercetin at 
20 µM (40.3% control ± 18.7%, P ≤ 0.05). 
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Figure 4. Graphs showing the absorbance at 450 nm after the CCK cytotoxicity assay. 
The left graph shows the dose-dependent cytoxic effects of ellagic acid and quercetin on 
HUVEC. The right graph shows the dose-dependent cytoxic effect of quercetin on TE-8 
cells, and the resistance of TE-8 cells to ellagic acid. Ellagic acid showed cytotoxicity in 
HUVECs at 1 µM (P ≤ 0.008), but was not cytoxic in TE-8 cells at the concentrations 
tested. Quercetin was cytoxic in HUVECs at 5 µM (P ≤ 0.002), and was cytoxic in TE-8 
cells at 10 µM (P ≤ 0.02). 
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